Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + ibrutinib + rituximab versus bendamustine + ibrutinib + rituximab in untreated mantle cell lymphoma
2022-501808-96-00Phase 2Authorised
- Sponsor
- University Medical Center Mainz
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of venetoclax, ibrutinib, rituximab and bendamustine in mantle cell lymphoma (MCL) (2 arms), sponsored by University Medical Center Mainz. Primary endpoint: Failure-free survival at 30 months. Planned start May 2023; status: authorised.
02
Drugs
venetoclaxibrutinibrituximabbendamustine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2022-501808-96-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501808-96-00.